Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLASH: Fludrocortisone in Aneurysmal Subarachnoid Haemorrhage
NCT06409364Phase 2Recruiting
- Sponsor
- The George Institute for Global Health
- Start
- Aug 2025
- Primary completion
- Jul 2029
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of fludrocortisone in aneurysmal subarachnoid hemorrhage (SAH) (2 arms), sponsored by The George Institute for Global Health. Primary endpoint: Modified Rankin Scale at 6 months. Started Aug 2025; status: recruiting.
02
Drugs
fludrocortisone
03
Conditions
aneurysmal subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on NCT06409364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06409364.